113712-98-4

113712-98-4 structure

Name: Tenatoprazole
Chemical Name: Tenatoprazole
CAS Number: 113712-98-4
Molecular Formula: C₁₆H₁₈N₄O₃S
Molecular Weight: 346.40
Catalog: Biochemical Inhibitor Transmembrane Transporters Proton Pump inhibitor
Create Date: 2018-07-06 00:26:10
Modify Date: 2024-01-03 12:23:57
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV[1][2][3].

Name	Tenatoprazole
Synonyms	5-Methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine (±)-5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine 1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- 5-Methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-3H-imidazo[4,5-b]pyridine tenatoprazole/tu-199 5-Methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridin Tenatoprazole 5-Methoxy-2-{[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl}-1H-imidazo[4,5-b]pyridine tenatoprazole monosodium

Description	Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV[1][2][3].
Related Catalog	Research Areas >> Infection Research Areas >> Inflammation/Immunology Signaling Pathways >> Membrane Transporter/Ion Channel >> Proton Pump
In Vitro	Tenatoprazole (TU-199) (0.1, 0.2, 0.4 mg/kg; oral; single; Heidenhain-pouch dogs) dose-dependently suppresses gastric acid secretion stimulated by histamine infusion[4].
References	[1]. Thomson AB, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study. Aliment Pharmacol Ther. 2006;23(8):1179-1187. [2]. Uchiyama K, et al. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods Find Exp Clin Pharmacol. 1999;21(2):115-122. [3]. Mannemuddhu SS, et al. Prazoles Targeting Tsg101 Inhibit Release of Epstein-Barr Virus following Reactivation from Latency. J Virol. 2021;95(13):e0246620. [4]. Uchiyama K, et al. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs. J Pharm Pharmacol. 1999;51(4):457-464.

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302-H315-H319-H335
Precautionary Statements	P301 + P312 + P330-P305 + P351 + P338
Hazard Codes	Xn: Harmful;
Risk Phrases	R22
Safety Phrases	26-36/37
RIDADR	NONH for all modes of transport

113713-24-9

~71%

113712-98-4

Precursor 1
113713-24-9
DownStream 0